Abstract
Immune thrombocytopenia (ITP) refractory to multiple therapies may require a combination of drugs targeting different mechanisms and targets. In this retrospective, multicentre, international study, we report the safety and effectiveness of avatrombopag and fostamatininb in combination administered to 18 patients with multirefractory ITP. Overall, the combination response was achieved in 15 patients (83.3%), with a median time from combination start to best response of 15 days (IQR: 8-35 days). After a median follow-up of 256 days (IQR: 142.8-319), 5 patients relapsed (26.7%), all during tapering or stopping one drug. Adverse events were described in 6 of 18 patients (33%).
Keywords:
ITP; SYK inhibitor; TPO‐RA; combining treatment.
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
MeSH terms
-
Adult
-
Aged
-
Aminopyridines / administration & dosage
-
Aminopyridines / adverse effects
-
Aminopyridines / therapeutic use
-
Drug Therapy, Combination*
-
Female
-
Humans
-
Hydrazines / administration & dosage
-
Hydrazines / adverse effects
-
Hydrazines / therapeutic use
-
Male
-
Middle Aged
-
Morpholines* / administration & dosage
-
Morpholines* / therapeutic use
-
Oxazines / administration & dosage
-
Oxazines / adverse effects
-
Oxazines / therapeutic use
-
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use
-
Retrospective Studies
-
Thiazoles
-
Thiophenes
-
Treatment Outcome
Substances
-
avatrombopag
-
fostamatinib
-
Morpholines
-
Pyridines
-
Pyrimidines
-
Oxazines
-
Aminopyridines
-
Pyrazoles
-
Hydrazines
-
Thiazoles
-
Thiophenes